Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 20;11(9):960.
doi: 10.3390/genes11090960.

Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations

Silvia Salmoiraghi  1   2   3 , Roberta Cavagna  1 , Marie Lorena Guinea Montalvo  1 , Greta Ubiali  1 , Manuela Tosi  1 , Barbara Peruta  1 , Tamara Intermesoli  1 , Elena Oldani  1 , Anna Salvi  1 , Chiara Pavoni  1 , Ursula Giussani  4 , Renato Bassan  5 , Alessandro Rambaldi  1   6 , Orietta Spinelli  1
Affiliations

Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations

Silvia Salmoiraghi et al. Genes (Basel). .

Abstract

Here, we describe the immunoglobulin and T cell receptor (Ig/TCR) molecular rearrangements identified as a leukemic clone hallmark for minimal residual disease assessment in relation to TP53 mutational status in 171 Ph-negative Acute Lymphoblastic Leukemia (ALL) adult patients at diagnosis. The presence of a TP53 alterations, which represents a marker of poor prognosis, was strictly correlated with an immature DH/JH rearrangement of the immunoglobulin receptor (p < 0.0001). Furthermore, TP53-mutated patients were classified as pro-B ALL more frequently than their wild-type counterpart (46% vs. 25%, p = 0.05). Although the reasons for the co-presence of immature Ig rearrangements and TP53 mutation need to be clarified, this can suggest that the alteration in TP53 is acquired at an early stage of B-cell maturation or even at the level of pre-leukemic transformation.

Keywords: TP53; acute lymphoblastic leukemia; immunoglobulin rearrangements.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict of interest to declare.

References

    1. Davi F., Faili A., Gritti C., Blanc C., Laurent C., Sutton L., Schmitt C., Merle-Beral H. Early onset of immunoglobulin heavy chain gene rearrangements in normal human bone marrow CD34+ cells. Blood. 1997;90:4014–4021. doi: 10.1182/blood.V90.10.4014. - DOI - PubMed
    1. Nemazee D. Receptor selection in B and T lymphocytes. Annu. Rev. Immunol. 2000;18:19–51. doi: 10.1146/annurev.immunol.18.1.19. - DOI - PMC - PubMed
    1. Bruggemann M., Raff T., Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120:4470–4481. doi: 10.1182/blood-2012-06-379040. - DOI - PubMed
    1. Cave H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., Bakkus M., Thielemans K., Grandchamp B., Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N. Engl. J. Med. 1998;339:591–598. doi: 10.1056/NEJM199808273390904. - DOI - PubMed
    1. Bassan R., Spinelli O., Oldani E., Intermesoli T., Tosi M., Peruta B., Rossi G., Borlenghi E., Pogliani E.M., Terruzzi E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood. 2009;113:4153–4162. doi: 10.1182/blood-2008-11-185132. - DOI - PubMed

Publication types